Keywords: European Commission, Roche, Avastin, Breast cancer

European Commission backs Roche’s Avastin/paclitaxel combo for metastatic breast cancer

Article | 04 March 2011

Print This

The European Commission has confirmed that Swiss drug major Roche’s (SIX: ROG) Avastin (bevacizumab) in combination with paclitaxel ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in